Q-omics provides the consensus-scored LRRC10 profile across patient tissues and cancer cell-line models. LRRC10 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC10 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, LRRC10 RNA expression shows 7,205 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight KIRC, and SCLC as cancer lineages where LRRC10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC10 survival associations across molecular data types. LRRC10 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC10 RNA expression–survival associations across cancer types. High LRRC10 expression shows unfavorable associations in KIRC, KICH, CESC and DLBC, but favorable associations in SCLC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC10 RNA expression.
This table summarizes LRRC10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC10 shows higher tumor expression in KIRC, KIRP and HNSC. The KIRC box plot shows higher LRRC10 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .005).
This table shows molecular features associated with LRRC10 in patient tissues and cancer cell lines. In patient samples, LRRC10 shows the broadest associations at the RNA and protein expression levels, with SCLC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
